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ABSTRACT: Inducing post-translational protein knockdown
is an important approach to probe biology and validate drug
targets. An eﬃcient strategy to achieve this involves expression
of a protein of interest fused to an exogenous tag, allowing tag-
directed chemical degraders to mediate protein ubiquitylation
and proteasomal degradation. Here, we combine improved
HaloPROTAC degrader probes with CRISPR/Cas9 genome
editing technology to trigger rapid degradation of endogenous
target proteins. Our optimized probe, HaloPROTAC-E, a
chloroalkane conjugate of high-aﬃnity VHL binder VH298,
induced reversible degradation of two endosomally localized
proteins, SGK3 and VPS34, with a DC50 of 3−10 nM.
HaloPROTAC-E induced rapid (∼50% degradation after 30 min) and complete (Dmax of ∼95% at 48 h) depletion of Halo-
tagged SGK3, blocking downstream phosphorylation of the SGK3 substrate NDRG1. HaloPROTAC-E more potently induced
greater steady state degradation of Halo tagged endogenous VPS34 than the previously reported HaloPROTAC3 compound.
Quantitative global proteomics revealed that HaloPROTAC-E is remarkably selective inducing only degradation of the Halo
tagged endogenous VPS34 complex (VPS34, VPS15, Beclin1, and ATG14) and no other proteins were signiﬁcantly degraded.
This study exempliﬁes the combination of HaloPROTACs with CRISPR/Cas9 endogenous protein tagging as a useful method
to induce rapid and reversible degradation of endogenous proteins to interrogate their function.
Technologies that enable the post-translational degradationof proteins allow interrogation of protein function and
facilitate validation of targets for therapeutics development.1
One approach to induce post-translational protein knockdown
is by means of proteolysis targeting chimeras (PROTACs),2
molecules capable of binding and recruiting an E3 ligase
machinery to target proteins, to induce their ubiquitylation and
proteasome-mediated degradation.3−5 A key advantage of
PROTAC degraders is their ability to induce time and dose-
dependent, reversible, and often complete depletion of target
proteins inside cells. PROTACs, however, require a ligand
capable of interacting with the desired target, and high-aﬃnity
ligands are lacking for the vast majority of human proteins. To
circumvent this, alternative strategies have been developed that
involve attaching various tags to target proteins, to enable these
to be targeted by a compound capable of inducing interaction
with an E3 ligase machinery.1,6,7 One of the ﬁrst approaches
made use of the plant E3 ligase TIR1, exogenously expressed in
non-plant cells, to trigger ubiquitylation and degradation of
target proteins fused to an Auxin-inducible degron (AID) tag on
addition of the plant hormone Auxin.8−10 A more recent
approach exploits the ability of a phthalimide-based chimeric
compound called dTAG to bind proteins fused with a mutant
FKBP12 tag and induce degradation via the cereblon (CRBN)
E3 ligase.11−14 CRBN is endogenously expressed in most
mammalian cells and, therefore, does not need to be
overexpressed. Other methods include deGradFP and Ad-
PROM, which rely on the overexpression of the von Hippel−
Lindau (VHL) E3 ligase fused to a GFP binding nanobody
capable of inducing degradation of GFP-tagged proteins,15−17 or
the Trim−AWAYmethod that enables the TRIM21 E3 ligase to
be recruited to targets via a speciﬁc antibody.18 These
technologies each have their own caveats; for example, AID is
prone to leakage without addition of its chemical inducer,19 and
phthalimide-based conjugates that target CRBN are prone to
chemical instability and oﬀ-target eﬀects.20,21 The AID,
ADPPROM, and Trim−AWAY methods all involve over-
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expression of E3 ligases that could ubiquitylate unknown oﬀ
target proteins. Antibodies employed for the TRIM−AWAY
method need to be introduced into cells, which is not
straightforward for many applications, and furthermore these
antibodies could also interact with unknown targets in cells. An
important aspect to all of these approaches is the ability to
introduce the various tags into the endogenous locus via gene
editing, for example using CRISPR/Cas9,22 in order to then
study the eﬀect of the targeted degradation on the endogenous
protein. However, this advance has only been achieved very
recently and in only a few cases.9,12 The use of these methods to
induce degradation of proteins of speciﬁc subcellular localization
also remains understudied.
To address these issues, we decided to further develop the
“HaloPROTAC” method. HaloPROTAC exploits a VHL
ligand23 or a cIAP ligand24 linked to a chloroalkane moiety
capable of forming a covalent bond with a tag termed HaloTag7,
a bacterial dehalogenase made more stable by introducing
multiple point mutations. As such, HaloPROTACs are designed
to induce ubiquitylation and degradation of HaloTag7 fusion
proteins. All work undertaken with the HaloPROTAC method
to date has been performed on over-expressed proteins, and has
not been demonstrated against endogenous targets. We have
recently described optimized VHL ligands, with improved
potency and speciﬁcity than previously described ligands, both
as inhibitors25,26 and conjugated into PROTACs.27−29 We
hypothesized that these optimized VHL ligands could be
incorporated into novel HaloPROTAC probes to permit
eﬃcient degradation of endogenous proteins fused to HaloTag7
employing CRISPR gene editing technology.
We were interested in investigating ligand-induced knock-
down of two target proteins localized at endosomes, namely
SGK3 (serum and glucocorticoid kinase-3) and VPS34 (Class
III PI 3-kinase). SGK3 is a member of the AGC protein kinase
family, bearing similarity and overlapping substrate speciﬁcity to
Akt.30 Like Akt, SGK3 is activated by phosphorylation on its T-
loop by PDK1 and hydrophobic motif by mTORC2. While Akt
activation is solely mediated by PI3K Class I, SGK3 is in
addition switched on downstream of the Class III PI3-kinase
termed VPS34.30,31 SGK3 interacts with PtdIns3P generated by
VPS34 at the endosomal membrane and this promotes
phosphorylation and activation by PDK1 and mTORC2.31
Recent studies suggest that the VPS34-SGK3 signaling axis
contributes to resistance of breast cancer cells to class I PI3K and
Akt inhibitor therapy.32 VPS34 also plays important roles in
endosomal membrane traﬃcking and autophagy.33
■ RESULTS AND DISCUSSION
Generation on Halo-VPS34 and SGK3-Halo Knock-in
Cell Lines. To generate endogenous HaloTag7 fusion proteins,
we utilized CRISPR/Cas9 gene-editing technology to attach the
HaloTag7 variant to the N-terminus of VPS34 and C-terminus
of SGK3 (Figure 1 and Methods). The tag was fused to the C-
terminus of SGK3, as previous work revealed that an N-terminal
tag impacted on PtdIns3P binding to the N-terminal PX
domain.30 Previous studies have located epitope tags at the N-
terminus of VPS34 and reported that this did not aﬀect ability to
activate SGK3.31 This also allowed comparison of whether the
HaloPROTAC method could be used to degrade endogenous
proteins coupled with N-terminal as well as C-terminal
HaloTag7 fusions. The CRISPR gene-editing was undertaken
Figure 1. Generation of HaloTag7 endogenous fusion proteins by CRISPR/Cas9. The D10A Nickase form of Cas9 was chosen for increased
speciﬁcity, and two guides were designed for each cell line.22 The SGK3-Halo donor also included an IRES2-eGFP cassette, allowing successfully
integrated cells to be selected through FACs sorting for GFP positive cells. The Halo-VPS34 donor contained HaloTag7 only. Cells were selected
through single cell sorting. Clones were selected and lysates screened by Immunoblot analysis, using antibodies against the endogenous proteins and a
mouse monoclonal antibody against HaloTag7. The clones were characterized by DNA sequencing. Clone wt (wild type) refers to parental HEK293
cells, and ko (knockout) refers to previously described SGK3-knockout cell line31
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in HEK293 cells that have been extensively deployed for the
analysis of the VPS34-SGK3 signaling pathway.30,31 These cells
are pseudotriploid,34 and carry three copies of SGK3 and VPS34
(HEK293genome.org). A total of four cell lines of each knock-in
were selected from Immunoblot analysis and subjected to DNA
sequencing analysis (Figure 1 and Supporting Information (SI)
Figure S1). All the selected Halo-VPS34 cell lines were
homozygous at the protein level (Figure 1), and DNA
sequencing revealed clones 42 and 56 to be homozygous, with
clones 55 and 80 containing knockout mutations in at least one
allele. In the case of SGK3-Halo, we failed to identify any
homozygous clones. Three clones contained one or two copies
of SGK3 fused to HaloTag7 with remaining allele(s) wild type,
and the fourth clone (Clone 2) possessed two copies of the
Figure 2. Localization and function of VPS34 and SGK3 are unaﬀected by fusion to HaloTag7. A−C. Parental 293 (A), Halo-VPS34 (B), and SGK3-
Halo (C) cells were treated for 15 min with HaloTag-TMR Ligand, and the ligand was washed out for 15 min. Cells were stained with Rab5 early
endosomal marker to detect localization of HaloTag fusion proteins on endosome. Assays were performed in the presence or absence of 1 μMVPS34-
IN1. D. Quantiﬁcation of PtdIns3P, measured using a 2XFYVE domain probe, colocalizing to Rab5 expressing endosomes in Parental 293 and Halo-
VPS34 cells. E. VPS34 was immunoprecipitated from Parental 293 and Halo-VPS34 cells, and immunoprecipitates were blotted for VPS34 complex
components. F. Parental 293, SGK3-KO, and SGK3-Halo cells were treated for 1 h with either Akt inhibitor AZD5363 (3 μM), SGK3 inhibitor 14H (1
μM), or both. Cells were lysed and immunoblotted for the targets described.
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SGK3-Halo knockin allele, with remaining copy of the SGK3
gene possessing a C-terminal truncation two residues away from
the functionally important hydrophobic motif, predicted to
destabilize the protein. The work described in this paper was
undertaken with Halo-VPS34 Clone 56 and SGK3-Halo Clone
2.
HaloTag7 Fusions Do Not Interfere with VPS34 and
SGK3 Function. To investigate to what extent the HaloTag7
fusion might impact on protein function, we initially studied the
localization of the Halo-VPS34 and SGK3-Halo employing the
HaloTag TMR Ligand from Promega, a ﬂuorescently labeled
probe that covalently reacts with HaloTag7 fusion proteins. In
the wild type HEK293 cells, as expected no signal above
background was detected (Figure 2A). In contrast in the Halo-
VPS34 (Figure 2B) and SGK3-Halo (Figure 2C) knock-in cells,
strong punctate staining co-localizing with the Rab5 early
endosomal marker was observed, consistent with previous
studies showing that VPS34 and SGK3 are located at the
endosome.30,31 We also treated cells with the highly selective
VPS34 inhibitor, VPS34-IN1,30 to reduce PtdIns-3P levels.
Consistent with previous work,30 VPS34-IN1 induced relocal-
ization of SGK3-Halo to the cytosol (Figure 2C). VPS34-IN1
appeared to strengthen endosomal localization of Halo-VPS34
(Figure 2B). We also analyzed PtdIns3P levels employing a
previously reported method35 in which ﬁxed cells are incubated
with the PtdIns-3P binding 2XFYVE-probe labeled with Alexa
Fluor-594 ﬂuorescent dye. This conﬁrmed endosomal local-
ization of PtdIns-3P was suppressed following treatment with
VPS34-IN1 (Figure 2D and SI Figure S2). The levels of
PtdIns3P were similar in the wild type and Halo-VPS34 knock-
in cells, suggesting that the Halo tag was not interfering with
VPS34 activity. To further verify that HaloTag does not impact
VPS34 complex stability, we immunoprecipitated VPS34 from
wild type and Halo-VPS34 knock-in cells with a previously
characterized VPS34 antibody and undertook Immunoblot
analysis for the other subunits. These experiments conﬁrmed
that the levels of co-immunoprecipitating VPS15, Beclin1,
Atg14, and UVRAG were unaﬀected by the Halo tag (Figure
2E). In order to determine potential eﬀects of the HaloTag on
SGK3 activity, we analyzed phosphorylation of the well
characterized SGK3 substrate NDRG1 at Thr34631 in
HEK293 wildtype, SGK3-Halo KI and SGK3 KO cells. As
NDRG1 is also phosphorylated on this site by the Akt kinases,
we assessed phosphorylation upon treatment with selective Akt
inhibitor (3 μM AZD536336) in the presence or absence of the
selective SGK3 inhibitor (1 μM14H37). This assay revealed that
SGK3 mediated phosphorylation of NDRG1 in wild type and
SGK3-Halo cells was similar and higher than observed in SGK3
knock-out cells (Figure 2F). Taken together, this evidence
suggests that the added Halo tag does not alter the function and
activity of SGK3 within the cell.
Elaboration of HaloPROTAC Compounds.We began our
ligand design by considering HaloPROTAC probes previously
described by Buckley et al. that include isoindolinone-based
HaloPROTAC3 (Figure 3a).23 Based on information from our
extensive structure−activity relationships and structure-based
design of VHL ligands,25,38 we hypothesized that substitution of
the isoindolinone moiety of HaloPROTAC3 with other groups,
optimized for VHL binding aﬃnity could improve degradation
activity (Figure 3b). In a ﬁrst set of compounds, we replaced the
isoindolinone group with N-acylamides of L-tert-leucine on the
left-hand side of the molecule (as in VHL ligand VH032),38
maintaining the chloroalkane linker attachment point at the
phenyl ring on the right-hand side (Figure 3c). We therefore
synthesized compounds A−B bearing linkers of 15 and 21
atoms, respectively. In a second compound set, the acetyl group
at the left-hand side was replaced with a cyclopropylcyanoacetic
moiety (as in VHL inhibitor VH29825) in compounds E, F,
while maintaining chloroalkane linkers of the same length as
HaloPROTACs A, B (Figure 3c). Additionally, we prepared two
HaloPROTACs (C, D) having linkers of 16 and 22 atoms length
respectively attached at the N-terminal acyl amine moiety of
VH032, a conjugation pattern explored previously albeit with
diﬀerent linker lengths (13 and 19 atoms) (Figure 3d).23
Evaluation of HaloPROTAC Compounds’ Ability to
induce Degradation of Halo-VPS34 and SGK3-Halo. We
treated the SGK3-Halo and Halo-VPS34 cell lines with 0.001-1
μMHaloPROTACs A−F for 48 h. Protein levels were analyzed
and quantiﬁed by Immunoblot analysis employing a mouse
monoclonal antibody that detects HaloTag7 speciﬁcally (Figure
4a−c). Three compounds, A, C, and E, induced degradation of
HaloTag fusion proteins under these conditions in a dose-
dependent manner (Figure 4a−c). These compounds contained
a three PEG unit in the linker between the chloroalkane and
Figure 3.Chemical structures of HaloPROTAC3 and Compounds A−F. A. Chemical structure of previously described HaloPROTAC3. B. Chemical
structure of VHL inhibitors VH032 and VH298. C−D General chemical structures of HaloPROTAC compounds A−F.
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VHL-binding moiety, whereas the non-active compounds
possessed a ﬁve PEG linker, in agreement with previous
observations that a three PEG linker is often optimal.23 Of the
three active compounds, HaloPROTACs A and E, derived from
the phenyl position weremuchmore active thanHaloPROTAC-
C, derived from the acetyl position. HaloPROTAC-E contains a
modiﬁed VHL-binding moiety derived from our latest
optimized VHL ligand VH298.25 HaloPROTAC-E achieved a
maximum degradation of 95% of both SGK3 and VPS34 target
proteins at 300 nM, with a DC50 between 3 and 10 nM (Figure
4a−c). In assays undertaken up to 10 μM HaloPROTAC-E we
did not observe a “hook eﬀect” (data not shown), previously
observed with some other degraders, where degradation is
decreased at high concentrations as formation of binary
complexes outcompetes the active ternary complex.39 Addition-
ally, HEK293 wildtype, Halo-VPS3, and Halo-SGK3 cells were
treated for 48 h with 0.001-1 μMHaloPROTAC-E and no eﬀect
on cell viability was observed by MTS assay (SI Figure S3A).
In order to visualize how HaloPROTAC-E mediated
degradation of Halo-VPS34 and SGK3-Halo aﬀected the
SGK3 signaling pathway, we monitored NDGR1 phosphor-
ylation at Thr346 on treatment with HaloPROTAC-E. All
conditions were performed in the presence of Akt inhibitors to
remove the eﬀect of Akt activity on NDRG1. This revealed that
treatment of SGK3-Halo and Halo-VPS34 HEK293 cells with
HaloPROTAC-E induced dephosphorylation of NDRG1 at
Thr346 (Figure 4D), conﬁrming that degradation of SGK3 has a
functional eﬀect.
Characterization of HaloPROTAC-E. We next sought to
further characterize HaloPROTAC-E by assessing kinetics of
degradation and validating the Cullin2-VHL mediated mecha-
nism of degradation. At 300 nM treatment, 50% degradation of
SGK3-Halo was achieved within 20−30 min and 50% Halo-
VPS34 within 1−2 h (Figure 5a). To study whether degradation
is reversible, we treated cells with HaloPROTAC-E for 24 h, and
after washout of the compound, quantiﬁed expression of Halo-
tagged SGK3 and VPS34. Increased expressions of SGK3 and
Figure 4. HaloPROTAC-mediated degradation of HaloTag7-fusion proteins. A. SGK3-Halo and Halo-VPS34 cell lines were treated for 48h with
increasing concentrations of each HaloPROTAC in parallel. Degradation of target protein measured by Immunoblot analysis for HaloTag7. B and C.
Quantiﬁcation of Western Blot intensity from A for SGK3-Halo (B) or Halo-VPS34 (C). Protein intensity was quantiﬁed and presented relative to an
untreated control. D. SGK3-Halo and Halo-VPS34 cells were treated for up to 24 h with 300 nM HaloPROTAC-E. One hour before lysis, all
conditions were treated with 1 μMAZD5363 to inhibit Akt activity. Cells were lysed and lysates analyzed by Immunoblot with the antibodies speciﬁed.
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VPS34 were observed 4 h after removal of HaloPROTAC-E.
Virtually normal levels of SGK3-Halo expression were observed
after 24 h (Figure 5b), but in the case of VPS34, levels were still
∼2-fold reduced after 48 h (SI Figure S3b). To conﬁrm
HaloPROTAC-E-mediated degradation of Halo-tagged SGK3
and VPS34 occurs through the Cullin2-VHL E3 Ligase,40,41 we
pre-treated cells with the Cullin E3 ligase Neddylation inhibitor,
MLN4924 (3 μM for 3 h prior to HaloPROTAC-E treatment)
and found that this blocked the ability of HaloPROTAC-E (300
nM, 4 h) to induce degradation of Halo-tagged SGK3 (Figure
5c) and VPS34 (SI Figure S3c), with PROTAC-induced protein
depletion reduced from 70% to 30%. Treatment of cells with the
proteasome inhibitor MG132 (50 μM, 0.5 h prior to
HaloPROTAC-E administration) had a similar eﬀect (Figure
5C and SI Figure S1B). Hif1α, the physiological substrate of
VHL, is stabilized on treatment withMLN4924 andMG132 due
to blockade of Hif1α ubiquitination and degradation. However,
Hif1α stabilization was not induced by treatment with 300 nM
HaloPROTAC-E (Figure 5C). This data demonstrates that
HaloPROTAC-E does not inhibit VHL when used at
concentrations (nanomolar range) where it is active for
ligand-induced protein degradation, in line with previous
observations with other VHL-based PROTAC compounds.4,27
To further conﬁrm degradation is VHL-dependent, we similarly
Figure 5. Mechanistic characterization of HaloPROTAC-E. A. SGK3-Halo and Halo-VPS34 cells were treated for up to 4 h with 300 nM
HaloPROTAC-E. Cells were lysed and probed byWestern Blot for HaloTag7, and quantiﬁed for percentage of remaining HaloTag7 protein. B. SGK3-
Halo cells were treated for 24 hwith 300 nMHaloPROTAC-E. After 24 h, cells were washed three times withDMEMand replaced with freshmedia for
the times indicated. Recovery of SGK3-Halo was analyzed by Immunoblot C. Halo-VPS34 cells were treated for 6 h with 300 nM HaloPROTAC-E,
after pre-inhibition of Cullin Neddylation byMLN4924 (3 μM for 3h) or Proteasome byMG132 (50 μM for 30 min). Cells were lysed and remaining
HaloTag7 fusion protein was analyzed by Immunoblot. C. SGK3-Halo and HaloVPS34 cells were treated for 6 h with 300 nMHaloPROTAC-E, after
pre-inhibition of VHL by 50 μM VH298 for 15 min.
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pretreated SGK3-Halo and Halo-VPS34 cells for 15 min with 50
μM VH298 before HaloPROTAC-E treatment, and again
observed substantial blockade of SGK3-Halo and HaloVPS34
degradation (Figure 5D).
We next undertook a side-by-side comparison on the ability of
HaloPROTAC-E and the previously reported HaloPRO-
TAC323 to induce dose (Figure 6A) and time (Figure 6B)
dependent degradation of Halo-VPS34. This revealed that
HaloPROTAC-E exhibited a greater potency at inducing
degradation of Halo-VPS34 than HaloPROTAC3 at any
concentrations tested below 300 nM. For example, 10 nM
HaloPROTAC-E for 24 h induced 65% degradation of Halo-
VPS34 compared to 50% of the same concentration of
HaloPROTAC3. Dose response degradation proﬁles revealed
an approximately 2-fold reduction in estimated DC50. At
concentrations 300 nM and above HaloPROTAC3 and
HaloPROTAC-E induced similar degradation at the 24 h time
point (Figure 6A). Time course analysis revealed that the rate of
degradation of Halo-VPS34 up to 30 min was very similar to
HaloPROTAC-E and HaloPROTAC3 (Figure 6B). However,
after 30 min, signiﬁcantly greater degradation of Halo-VPS34
was observed with HaloPROTAC-E. At 1−4 h, ∼75%
degradation of Halo-VPS34 is observed with HaloPROTAC-E
compared to ∼50% with HaloPROTAC3 (Figure 6B).
As shown in Figure 2C, SGK3-Halo is endosomally localized,
and on treatment with VPS34-IN1 translocates to the cytosol.
We compared the rate at which endosomal (DMSO) versus
cytosolic (1 μM VPS34-IN1) SGK3-Halo was degraded by
HaloPROTAC-E and observed that both rate of degradation
andDmax at 24 h were similar in both conditions (Figure 7A).We
were similarly able to visualize degradation of endosomal and
cytosolic SGK3-Halo by immunoﬂuorescence (Figure 7B−F).
Striking Speciﬁcity of HaloPROTAC-E. To establish the
speciﬁcity of HaloPROTAC-E-induced protein degradation, we
performed quantitative tandem-mass-tag (TMT)-labeled global
proteomic analysis of Halo-VPS34 cells treated in the presence
or absence of 300 nM HaloPROTAC-E for 4 h. Experiments
undertaken in quadruplicate and analyzed in Proteome
Discoverer v2.2 using Mascot search engine allowed relative
quantiﬁcation of 9786 proteins. This unbiased analysis revealed
that HaloPROTAC-E was remarkably selective. Only protein
levels of Halo-VPS34 (70% reduction) and its known regulatory
subunits VPS15 (50% reduction), Beclin1 (20% reduction),
ATG14 (30% reduction), and UVRAG (15% reduction) were
impacted to statistically signiﬁcant level (p value <10−4) (Figure
8A and SI Table S1). It is indeed striking that no other cellular
protein was reduced by HaloPROTAC-E. Immunoblot analysis
conﬁrmed reduction of Halo-VPS34, VPS15, and Beclin1
expression induced by HaloPROTAC-E (Figure 8B). Time
course analysis of VPS34 degradation revealed that at very early
time points of 10−20 min, VPS15 was reduced at a similar rate
to VPS34, whereas the reduction in Beclin1 expression was
slower (Figure 8C−D). It should be noted that a previous study
also observed degradation of VPS15 and Beclin1 when VPS34
expression was reduced using the ADPROM method.31 The
VPS34 regulatory subunits could be degraded due to loss of
stability when they are not in a complex, a hypothesis that is
supported by previous siRNA knock-down data.42 In addition,
we cannot rule out that these subunits could be degraded
through a “by-stander” eﬀect, by receiving collateral ubiquitina-
tion by the VHL ligase as a result of being part of the same
complex.29
Conclusion. In summary, we describe the design and
synthesis of a novel potent HaloPROTAC compound, termed
HaloPROTAC-E, and show that this induces the rapid and
eﬃcient degradation of two endogenously HaloTag fusion
proteins, SGK3 and VPS34. HaloPROTAC-E induced potent
degradation, with a DC50 between 3 and 10 nM. Our
quantitative mass spectrometry studies reveal that this is
markedly selective, not degrading any other proteins other
than the Halo-VPS34 and its known regulatory subunits. The
rate of degradation of SGK3 (20−30 min for 50% degradation)
was slightly more rapid than observed with VPS34 (1−2 h for
50% degradation) which is part of a complex. The dynamics of
degradation were similar for both N-terminally tagged VPS34
and C-terminally tagged SGK3 suggesting that the tag can be
Figure 6. Comparison of HaloPROTAC-E to previously reported HaloPROTAC3. A. Halo-VPS34 cells were treated in parallel for 24 h with 1-1000
nMHaloPROTAC-E or HaloPROTAC3. Cells were lysed and remaining HaloTag7 fusion protein was analyzed by Immunoblot. B. Halo-VPS34 cells
were treated for up to 4 h with 300 nM HaloPROTAC-E or HaloPROTAC3. Cells were lysed and probed by Western Blot for HaloTag7, and
quantiﬁed for percentage of remaining HaloTag7 protein.
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attached to either end of a protein and that the approach is
generalizable to other proteins. The HaloPROTAC compound
described in this study was also shown to be more eﬀective than
the previously reported compound HaloPROTAC3. As VPS34
and SGK3 are localized at the endosome, our data demonstrate
that the HaloPROTAC approach is suitable for degrading
endosomal proteins. We would expect this technology to be
applicable to cells beyond HEK293 cells. The limitation of the
HaloPROTAC approach lies in the ability to generate
homozygous HaloTag7 knock-in fusions. Using the current
gene editing technology there are still challenges with obtaining
the desired knock-in in all alleles. Screening of a large number of
positive clones may be required, but with rapidly improving
eﬃciency of gene editing technology, it should become more
possible to generate these mutations rapidly. Some compromise
may be needed, as in the case of SGK3-Halo (2 knock-in and 1
destabilized allele).
Because the chloroalkane handle reacts covalently with
HaloTag7, a potential limitation of HaloPROTACs is that
stoichiometric occupancy of the tagged protein is required to
Figure 7. HaloPROTAC-E induces degradation of endosomally localized proteins. A. SGK3-Halo cells were treated for up to 24 h with 300 nM
HaloPROTAC-E alone, or in combination with VPS34IN1 at 1 μM. Cells were lysed, and remaining SGK3-Halo was analyzed by Immunoblot. B−F.
HEK293 cells were transfected for 24 h for SGK3-Halo expression, and treated for 8h with 1 μMHaloPROTAC-E in the presence or absence of 1 μM
VPS34-IN1 before ﬁxing and staining for HaloTag7 and endosomal marker Rab5. SGK3-Halo was overexpressed to facilitate detection and
quantitation. Anti-HaloTag7 antibody was detected with Alexa Fluor-594 coupled secondary, and Rab5 by Alexa Fluor-488 coupled secondary
antibodies.
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achieve complete degradation of the target protein. This is not
the case of PROTACs bearing non-covalent target ligands,
which instead can function catalytically at sub-stoichiometric
concentrations relative to the target protein. Despite the clear
strengths of non-covalent protein degradation modalities,
potent ligands are often required, and structure-guided
PROTAC design requires structural information on ternary
complexes.28 Even with this knowledge, many variables aﬀecting
eﬃcacy of PROTACs are still not thoroughly understood, and
are highly target dependent. The HaloPROTAC approach
removes these issues, allowing for exquisite selectivity and high
aﬃnity. Our improved HaloPROTAC approach, combining
HaloPROTAC-E with CRISPR/Cas9 mediated endogenous
protein tagging, provides a useful tool to interrogate an
endogenous system and validate the therapeutic potential of
degrading its protein target.
■ METHODS
Biology. Materials. Triton X-100, EDTA, EGTA, sodium
orthovanadate, sodium glycerophosphate, sodium ﬂuoride, sodium
pyrophosphate, 2-mercaptoethanol, sucrose, benzamidine, Tween 20,
Tris-HCl, and sodium chloride were from Sigma. Tissue culture
reagents, Novex 4-12% Bis-Tris gels and NuPAGE LDS sample buﬀer
were from Invitrogen. Polyethylenimine was from Polysciences.
Ampicillin was from Merck. CellTiter 96 AQueous One Solution Cell
Proliferation Assay (MTS) was from Promega. Plasmids used in the
present study were generated by the MRC-PPU reagents and Services
team (https://mrcppureagents.dundee.ac.uk/). All DNA constructs
were veriﬁed by DNA sequencing, performed by the MRC-PPU DNA
Sequencing and Service (http://www.dnaseq.co.uk). All constructs are
available to request from the MRC-PPU reagents webpage (http://
mrcppureagents.dundee.ac.uk), and the unique identiﬁer (DU)
numbers indicated provide direct links to the cloning and sequence
details.
Cell Culture, Treatments, and Cell Lysis. HEK293 cells were
purchased from the American Tissue Culture Collection and cultured
in DMEM supplemented with 10% (v/v) fetal bovine serum, 2 mM L-
glutamine, 100 U/mL penicillin, and 0.1 mg mL−1 streptomycin. Cell
treatments were carried out as described in ﬁgure legends. The cells
were lysed in buﬀer containing 50 mM Tris-HCl (pH 7.5), 1 mM
EGTA, 1 mM EDTA, 1% (v/v) Triton X-100, 1 mM sodium
orthovanadate, 50 mM NaF, 5 mM sodium pyrophosphate, 0.27 M
sucrose, 10 mM sodium 2-glycerophosphate, 0.2 mM phenyl-
methylsulfonyl ﬂuoride, and 1 mM benzamidine. Lysates were clariﬁed
by centrifugation at 16 000g for 10 min at 4 °C. Protein concentration
was calculated using the Bradford assay (Thermo Scientiﬁc).
Immunoblotting was performed using standard procedures. The signal
was detected using a Licor Biosciences Odessey System and signal
quantiﬁed in Image Studio Lite.
Antibodies. The following antibodies were raised in sheep, by the
MRC-PPU reagents and Services team (https://mrcppureagents.
dundee.ac.uk/) and aﬃnity-puriﬁed against the indicated antigens:
anti-Vps34 (S672B; third bleed; raised against full-length human
Vps34) (DU3303), anti-Beclin1 (S900B; ﬁrst bleed; raised against full-
length human Beclin1) (DU7159), anti-UV-RAG (S323D; third bleed;
raised against full-length human UV-RAG) (DU 36785), anti-SGK3
(S848D, sixth bleed; raised against human SGK3 PX domain
comprising residues 1−130 of SGK3) (DU2034).
Anti-HaloTag7 was from Promega (G9211, G9281), anti-GAPDH
was from Santa Cruz (sc−32233), Anti-VPS15 (14580S) and Rab5
(E6N8S) was purchased from Cell Signaling Technology. Anti-ATG14
was from MBL Life Science (PD026) Secondary antibodies coupled to
IRDye680LT or IRDye800CW were obtained from Licor Biosciences.
Secondary antibodies coupled to Horseradish Peroxidase (HRP) were
obtained from Thermo Scientiﬁc. Secondary antibodies coupled to
Alexa Fluor 488 and Alexa Fluor 594 were obtained from Thermo
Scientiﬁc.
Generation of HaloTag7 Knock-in Cell Lines Using CRISPR-Cas9
Genome Editing. A modiﬁed Cas9 nickase system22 was used for the
generation of N-terminal HaloTag7-VPS34, and C-terminal SGK3-
HaloTag7 knock-in mutation. Optimal sgRNA pairs were identiﬁed (as
close as possible to point of HaloTag7 insertion, with a low combined
oﬀ-targeting score; (VPS34-sgRNA1: GCTACATCTATAGTTGT-
GACC (DU52071); sgRNA2: GCCCCATCGCACCGTCTGCAA
(DU52082); SGK3-sgRNA1: GAGCAAAATAAGTCTATAGA
(DU52684)); sgRNA2: GAAAAATAAGTCTTCTGAAGG
Figure 8. Degradation of HaloTag7 fusions is highly speciﬁc and has a biological impact. A. Volcano plot quantifying proteins signiﬁcantly
downregulated on 4 h HaloPROTAC-E treatment in Halo-VPS34 cells. B. Immunoblot analysis of lysates taken for mass spectrometry analysis. C and
D. HaloVPS34 cells were treated with 0.3 μMHaloPROTAC-E for up to 4 h. C. Immunoblot analysis of these lysates for VPS34 complex members. D.
Quantiﬁcation of relative protein levels of VPS34 complex members from 8C.
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.8b01016
ACS Chem. Biol. 2019, 14, 882−892
890
(DU52662)) using the Sanger Institute CRISPR web tool (http://
www.sanger.ac.uk/htgt/wge/ﬁnd_crisprs). Complementary oligos
with BbsI compatible overhangs were designed for each, annealed,
and the dsDNA guide inserts ligated into BbsI-digested target vectors;
the antisense guides (sgRNA2) were cloned onto the spCas9 D10A-
expressing pX335 vector (Addgene plasmid no. 42335) and the sense
guides (sgRNA1) into the puromycin-selectable pBABED P U6
plasmid (Dundee-modiﬁed version of the original Cell Biolabs pBABE
plasmid). Donor constructs (VPS34-DU57077 and SGK3-DU52689)
consisting of HaloTag7 or HaloTag7-IRES2-GFP ﬂanked by ∼500 bp
homology arms were synthesized by GeneArt (Life Technologies);
each donor was engineered to contain suﬃcient silent mutations to
prevent recognition and cleavage by Cas9 nuclease.
HEK293 knock-in cell lines were generated using 1ug each of
appropriate guide plasmids and an additional 3 μg of donor plasmid.
Sixteen hours post-transfection, cell selection was carried out using 2
μg/mL puromycin for 2 days. Transfections were repeated without
puro selection prior to single-cell sorting by FACS, SGK3-Halo-IRES2-
GFP cells were additionally sorted for GFP expression. Single cells were
plated in individual wells of 96-well plates and viable clones were
expanded. Integration of HaloTag7 at the target locus for knock-in
clones was veriﬁed by Western blotting and genomic DNA sequencing
of the targeted locus.
Immunoﬂuorescence and PtdIns3P 2XFYVEDomain Staining. For
visualization of endogenous Halo-VPS34 and SGK3-Halo, in-cell
labeling of HaloTag7 fusion proteins was performed by adding
HaloTag TMR Ligand to a ﬁnal concentration of 5 μM for 15 min,
followed by a 15-minute washout of unbound ligand with fresh DMEM.
Following treatments described in ﬁgure legends, cells were ﬁxed with
4% (v/v) paraformaldehyde and permeabilized with 1% (v/v) NP-40.
Cells were blocked using 1% Bovine Serum Albumin (BSA) in PBS,
then incubated for 1 h with primary antibody, washed three times in
0.2% BSA in PBS, and incubated for 1 h again with secondary antibody.
For localization to endosomal compartments, Rab5 was stained with
anti-Rab5 antibody and secondary anti-mouse secondary conjugated to
Alexa Fluor 488. For detection of overexpressed SGK3-Halo protein,
HaloTag7 was stained with anti-HaloTag7 pAb and anti-rabbit
secondary conjugated to Alexa Fluor 594. Coverslips were washed
once more in water and mounted using ProLong Gold Antifade
(ThermoFisher #P36931).
For selective PtdIns3P staining, the GST-tagged HRS 2XFYVE
domain probe, coupled to Alexa Fluor 594 was kindly donated by the
Ganley laboratory. In short, the GST-tagged HRS 2× FYVE domain
(residues 147-223) were expressed in Escherichia coli (BL21) and
puriﬁed over a glutathione column using standard procedures. The
recombinant protein was chemically conjugated to Alexa Fluor 594
using the Alexa Fluor Microscale Protein Labeling Kit (no. A30008) as
per the manufacturer’s protocol. For staining, a similar protocol
described earlier was followed.43 Following treatment described in the
ﬁgure legends, cells were washed once on ice with phosphate-buﬀered
saline and glutamate buﬀer (25 mMHEPES (pH 7.4), 25 mMKCl, 2.5
mM Mg acetate, 5 mM EGTA, 150 mM potassium glutamate).
Coverslips were then immediately snap frozen in liquid nitrogen and
thawed at RT for 0.5 min prior to two further washes with ice cold
glutamate buﬀer prior to ﬁxing by incubating cells in 3.7% (w/v)
formaldehyde, 200 mM HEPES (pH 7.4). After 30 min at RT, ﬁxed
cells were quenched by incubating twice for 10 min in 10 mMHEPES,
pH 7.4, and DMEM at RT. Coverslips were then blocked and stained as
described above.
The images were collected on an LSM710 laser scanning confocal
microscope (Carl Zeiss) using the ×63 Plan-Apochromat objective
(NA 1.4), using a pinhole chosen to provide a uniform 0.8 um optical
section thickness in all the ﬂuorescence channels. For quantiﬁcation,
images from the microscope were imported into Volocity image
processing software (PerkinElmer) and batch-processed using the same
customwritten programmes for all the images in an experimental group.
For example, in each image, endosomes were identiﬁed from the Rab5
antibody staining, and the intensity of HaloTag7 protein or PtdIns3P in
these objects was collected as the sum of the pixel intensities,
normalized for the number of cells in each image. The graphs show the
average sum of the intensity per cell in arbitrary units. Each treatment
was repeated three times, and graphs shown are from representative
experiments.
CoImmunoprecipitation.Cells were lysed in standard lysis buﬀer as
described above. Endogenous VPS34 was Immunoprecipitated with a
speciﬁc VPS34 antibody (S672B; third bleed, MRCPPU Reagents and
Services), and beads were washed twice in the same lysis buﬀer +0.15M
NaCl (ﬁnal). Protein was eluted from beads using 2X LDS Sample
Buﬀer with 5% v/v Beta-Mercaptoethanol, and coimmunoprecipitating
proteins detected by Western Blot.
Supplementary Methods. Full Chemistry and Mass Spectrometry
Methods are provided in the Supporting Information
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